Could gene therapy with neurotrophic factors help restore dopaminergic terminals in Parkinson’s disease? Dr. Michele Matarazzo speaks with Dr. Amber Van Laar about her team’s Phase 1b trial of AAV2–GDNF gene therapy delivered directly to the putamen. They discuss the preclinical evidence for GDNF, how advanced delivery techniques and higher putamen coverage may overcome past challenges, and the encouraging early results in moderate Parkinson’s. The conversation also explores lessons from previous trials, safety outcomes, and the path forward.

Journal CME is available until June 25, 2026

Read the article.